CYTOTECT® BIOTEST BRIEF DESCRIPTION

Cytotect® Biotest is a world-leading hyperimmunoglobulin for treating human cytomegalovirus (CMV) infections and the virus represents a major viral pathogen in immunocompromised patients, especially in transplant recipients.

The combination of Cytotect®Biotest with virostatic drugs such as ganciclovir in the prophylaxis of CMV infections has shown improved outcome compared to prophylaxis with either agent alone 1, 2.

Unlike virostatic drugs, Cytotect®Biotest is not associated with nephrotoxic and neutropenic side effects, and no CMV immunoglobulin-resistant diseases have been reported. Additionally, Cytotect®Biotest contains elevated titers of antibodies against Epstein-Barr Virus (EBV), so as a favorable side effect, Cytotect®Biotect may also have a prophylactic role against EBV infections.

In summary, Cytotect®Biotest, in combination with virostatic drugs, may be more effective in controlling CMV infections than virostatic drugs alone.



1. Valantine, H.A., et al. (2001) Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation 72, 1647-1652

2. George, M.J., et al. (1993) Use of ganciclovir plus cytomegalovirus immune globulin to treat CMV pneumonia in orthotopic liver transplant recipients. The Boston Center for Liver Transplantation CMVIG-Study Group. Transplant Proc 25, 22-24